|
|
Article: Neurocrine Reports Two Additional Phase III Trials Demonstrating Indiplon Is Safe and Effective in Treating Elderly Patients With Difficulties Initiating and Maintaining Sleep; Results in Over 7000 Subjects to Date Support Efficacy and Safety for Sleep Initiation, Sleep Maintenance, and Long-Term Treatment.
- Article from:
- PR Newswire
- Article date:
- April 7, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced preliminary positive results from two of the Company's Phase III clinical trials. The trials reported today evaluated the two formulations of indiplon, immediate release and modified release, in elderly patients with chronic insomnia. Neurocrine has now completed Phase I, II and III clinical trials in over 7000 subjects to date in one of the most comprehensive clinical programs in insomnia to address the multiple needs of younger and older adult patients with insomnia such as sleep initiation, sleep maintenance, middle of the night awakenings, and long-term administration. Neurocrine is moving forward to complete regulatory ...